NCT01719315

Brief Summary

The goal of this project is to examine the neurophysiology of hypersomnia during sleep and wakefulness, to identify biomarkers for excessive sleepiness in neuropsychiatric disorders, and pilot acoustical slow wave induction during sleep in patients with hypersomnolence, to determine if this decreases daytime sleepiness in these patients. The primary study hypotheses are that individuals with hypersomnolence will have reduced slow wave activity (SWA) during sleep and increased waking theta/alpha activity during wake in specific brain regions. A secondary hypothesis is that acoustical slow wave induction in hypersomnolent patients will increase SWA during sleep, reduce theta/alpha activity during wake, and improve subjective sleepiness.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
76

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2012

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 24, 2012

Completed
8 days until next milestone

First Posted

Study publicly available on registry

November 1, 2012

Completed
Same day until next milestone

Study Start

First participant enrolled

November 1, 2012

Completed
5.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2018

Completed
Last Updated

December 24, 2018

Status Verified

December 1, 2018

Enrollment Period

5.6 years

First QC Date

October 24, 2012

Last Update Submit

December 21, 2018

Conditions

Outcome Measures

Primary Outcomes (1)

  • Nocturnal Slow Wave Activity

    EEG recordings during sleep will be analyzed to assess slow wave activity in the 1-4.5Hz range.

    Individual nights of sleep recorded within an average of 4 weeks of enrollment

Secondary Outcomes (1)

  • Waking theta/alpha activity

    Individual days of waking EEG will be recorded within an average of 4 weeks of enrollment

Study Arms (8)

MDD with Hypersomnia

Participants with Major Depressive Disorder and co-morbid hypersomnia

Other: Acoustical slow wave induction

MDD without hypersomnia

Participants with Major Depressive Disorder but without co-morbid hypersomnia

BPAD with hypersomnia

Participants with Bipolar Affective Disorder and co-morbid hypersomnia

Other: Acoustical slow wave induction

BPAD without hypersomnia

Participants with Bipolar Affective Disorder without co-morbid hypersomnia

Primary Hypersomnia

Patients with primary hypersomnia (idiopathic hypersomnia)

Other: Acoustical slow wave induction

Primary Insomnia

Patients with primary insomnia

Narcolepsy

Subjects with narcolepsy

Other: Acoustical slow wave induction

Healthy Controls

healthy participants

Interventions

Brief tones (50 millisecond duration) at a frequency of 0.8 and 2 Hz, a rate that approximates the natural cellular oscillations of cortical neurons during sleep, will be played in blocks of 15-20 during non-rapid eye movement (NREM) sleep. Blocks of active acoustic slow wave induction will be followed by blocks of equal duration without induction, in order to make comparisons between stimulation periods (ON) and no stimulation periods (OFF). Tone intensity will be manually adjusted so as to be above an individual participant's auditory threshold during waking, but still quiet enough as not to awaken the subject from sleep. Sham slow wave induction will consist of auditory tones played prior to sleep, and during sleep of insufficient timing and intensity to alter slow wave activity.

BPAD with hypersomniaMDD with HypersomniaNarcolepsyPrimary Hypersomnia

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Subjects will be recruited from the greater Madison, WI area. Hypersomnolent subject groups (n=30 in each group) may include unipolar MDD with hypersomnolence, primary hypersomnia (idiopathic hypersomnia), bipolar disorder with hypersomnolence, and narcolepsy. Non-hypersomnolent comparison groups (n=30 in each group) will include: MDD without hypersomnolence, bipolar disorder without hypersomnolence, primary insomnia, and healthy controls.

You may qualify if:

  • Meet Diagnostic and Statistical Manual edition IV criteria for neuropsychiatric disorders enumerated in study population description

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Wisconsin-Madison, Department of Psychiatry

Madison, Wisconsin, 53719, United States

Location

MeSH Terms

Conditions

Depressive Disorder, MajorIdiopathic HypersomniaBipolar DisorderNarcolepsySleep Initiation and Maintenance Disorders

Condition Hierarchy (Ancestors)

Depressive DisorderMood DisordersMental DisordersDisorders of Excessive SomnolenceSleep Disorders, IntrinsicDyssomniasSleep Wake DisordersNervous System DiseasesBipolar and Related Disorders

Study Officials

  • David T Plante

    University of Wisconsin, Madison

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 24, 2012

First Posted

November 1, 2012

Study Start

November 1, 2012

Primary Completion

June 1, 2018

Study Completion

June 1, 2018

Last Updated

December 24, 2018

Record last verified: 2018-12

Locations